EGFR and glioblastoma: EGFR Amp was confirmed as a significant prognostic biomarker for all IDH-wildtype diffuse glioma, histologic grade 2 and 3 IDH-wildtype diffuse astrocytic gliomas and GBM, but a limited one for IDH-mutant diffuse glioma and its subtypes.